Searched for
AUROBINDO ASSOCIATE
Buy Aurobindo Pharma, target price Rs 763: ICICI DirectAurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 44792.08 Crore) operating in Pharmaceuti...- Sell Aurobindo Pharma, target price Rs 597.5: ICICI DirectAurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 35144.60 Crore) operating in Pharmaceuti...
- Buy Aurobindo Pharma, target Rs 820: Kunal BothraBuy Aurobindo Pharma Ltd. at a price target of Rs 820 and a stoploss at Rs 770 from entry point.
- Buy Aurobindo Pharma, target Rs 805: Kunal BothraBuy Aurobindo Pharma Ltd. at a price target of Rs 805.0 and a stoploss at Rs 765 from entry point.
- Buy Aurobindo Pharma, target Rs 750: Dr CK NarayanBuy Aurobindo Pharma Ltd. at a price target of Rs 750.0 and a stoploss at Rs 725 from entry point.
- Buy Aurobindo Pharma, target Rs 825: Kunal BothraBuy Aurobindo Pharma Ltd. at a price target of Rs 825.0 and a stoploss at Rs 775 from entry point.
- Buy Aurobindo Pharma, target Rs 630: Dr CK NarayanBuy Aurobindo Pharma Ltd. at a price target of Rs 630.0 and a stop loss at Rs 610 from the entry point.
- Sell Aurobindo Pharma, target Rs 568: Dr CK NarayanSell Aurobindo Pharma Ltd. at a price target of Rs 568.0 and a stop loss at Rs 585 from entry point.
- Buy Aurobindo Pharma, target Rs 610: Manas JaiswalBuy Aurobindo Pharma Ltd. at a price target of Rs 610.0 and a stop loss at Rs 574 from entry point.
- Buy Aurobindo Pharma, target Rs 722: Kunal BothraBuy Aurobindo Pharma Ltd. at a price target of Rs 722.0 and a stoploss at Rs 668 from entry point.
- Buy Aurobindo Pharma, target Rs 850: Kunal BothraBuy Aurobindo Pharma at a price target of Rs 850 and a stop loss at Rs 750 from the entry point.
- Buy Aurobindo Pharma, target Rs 785: Shrikant ChouhanBuy Aurobindo Pharma at a price target of Rs 785 and a stop loss at Rs 732 from entry point.
- Aurobindo gets USFDA nod to market mental illness drugAccording to IMS sales data, the product had a market size of around USD 690 million for the twelve months ended March 2014.
- Aurobindo Pharmaceuticals gets USFDA nod for nausea injectionsThe injections are the generic equivalent of GlaxoSmithKline's Zofran injection, Aurobindo Pharma said.
- Aurobindo Pharma gets USFDA nod for Modafinil tablets"The company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Modafinil tablets USP 100mg and...
- Aurobindo Pharma gets USFDA approval for anti-depressantAurobindo Pharma said it has received final approval from the US health regulator to manufacture generic version of Lexapro.
- Aurobindo Pharma forms JV with Russian Ojsc Diod for generic productsAurobindo Pharma on Wednesday said it has formed an equal joint venture with Russian healthcare equipment company Ojsc Diod.
- Buy Aurobindo Pharma: Deepak MohoniBuy Aurobindo Pharma now and if the index is past 5700, this should give very good returns over the next 3-4 months.
- Buy Aurobindo Pharma for a target of 955: Huseini Vadharia, Techno Shares and Stocks Ltd.Huseini Vadharia, Senior Associate Technical Analysis, Techno Shares and Stocks Ltd. spoke to ET Now on Aurobindo Pharma.
- Aurobindo gets USFDA nod for anti-depressantDrug major Aurobindo Pharma on Wednesday said it has got tentative USFDA approval to market escitalopram oxalate tablets.
Load More
